Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
A client with type 1 diabetes is receiving insulin therapy. The nurse observes the patient experiencing symptoms such as sweating, trembling, and confusion. What is the nurse’s first action?
A. Administer simple, fast-acting carbohydrates to the client
Sweating, trembling, and confusion indicate hypoglycemia in type 1 diabetes, likely from excess insulin. Administering fast-acting carbohydrates (e.g., glucose tablets, juice) rapidly raises blood glucose by providing readily absorbable sugars, reversing neuroglycopenic symptoms. This is the first action to prevent seizures or coma, ensuring immediate stabilization.
B. Administer the prescribed dose of insulin since it was not yet given
Administering insulin during hypoglycemia would further lower blood glucose, exacerbating symptoms and risking severe outcomes like unconsciousness. Insulin drives glucose into cells, worsening the deficit. This action is contraindicated and dangerous, as it directly opposes the need to raise blood sugar immediately.
C. Order the client a meal with complex carbohydrates and proteins
Complex carbohydrates and proteins digest slowly, providing delayed glucose release, unsuitable for acute hypoglycemia requiring rapid correction. While appropriate for long-term glucose stability, this is not the first action, as it fails to address the urgent need for fast-acting sugars to reverse symptoms.
D. Call the healthcare provider to change the prescription for insulin
Calling the healthcare provider delays treatment of hypoglycemia, which requires immediate carbohydrate administration to prevent neurological damage. While provider consultation may follow for insulin adjustment, it is not the first action. This choice is inappropriate, as it postpones critical intervention needed for symptom resolution.
This question is an excerpt from Nurse Dive's nursing test bank - Pathophamacology Proctored Exam (Examplify). Take the full exam now
Full Explanation
Choice A reason: Sweating, trembling, and confusion indicate hypoglycemia in type 1 diabetes, likely from excess insulin. Administering fast-acting carbohydrates (e.g., glucose tablets, juice) rapidly raises blood glucose by providing readily absorbable sugars, reversing neuroglycopenic symptoms. This is the first action to prevent seizures or coma, ensuring immediate stabilization.
Choice B reason: Administering insulin during hypoglycemia would further lower blood glucose, exacerbating symptoms and risking severe outcomes like unconsciousness. Insulin drives glucose into cells, worsening the deficit. This action is contraindicated and dangerous, as it directly opposes the need to raise blood sugar immediately.
Choice C reason: Complex carbohydrates and proteins digest slowly, providing delayed glucose release, unsuitable for acute hypoglycemia requiring rapid correction. While appropriate for long-term glucose stability, this is not the first action, as it fails to address the urgent need for fast-acting sugars to reverse symptoms.
Choice D reason: Calling the healthcare provider delays treatment of hypoglycemia, which requires immediate carbohydrate administration to prevent neurological damage. While provider consultation may follow for insulin adjustment, it is not the first action. This choice is inappropriate, as it postpones critical intervention needed for symptom resolution.
Similar Questions
A client with chronic kidney disease has a low red blood cell count. What is the best response by the nurse?
A. Your kidneys are allowing a lot of red blood cells to leak out in your urine and causing you to become anemic
Chronic kidney disease (CKD) does not primarily cause anemia by leaking red blood cells (RBCs) into urine. While hematuria may occur in some renal conditions, anemia in CKD results mainly from reduced erythropoietin production, not RBC loss. This statement is inaccurate, as it misrepresents the primary mechanism of anemia in CKD.
B. The inflammatory process attacking your kidneys is also attacking your red blood cells
Inflammation in CKD may contribute to anemia by suppressing erythropoiesis through cytokine release, but it does not directly attack RBCs. The primary cause is erythropoietin deficiency due to impaired renal function. This statement is inaccurate, as it overstates inflammation’s role and ignores the key hormonal mechanism in CKD-related anemia.
C. The high pressure in your vessels that caused damage to your kidneys is also causing your red blood cells to burst
High vascular pressure in CKD can damage kidneys but does not directly cause RBCs to burst (hemolysis). Anemia in CKD stems from reduced erythropoietin, not mechanical RBC destruction. This statement is inaccurate, as it incorrectly links hypertension’s renal effects to direct RBC damage, misrepresenting the anemia’s cause.
D. Your kidneys are not able to synthesize the hormone responsible for stimulating red blood cell production
CKD causes anemia due to reduced erythropoietin synthesis by damaged kidneys. Erythropoietin stimulates RBC production in bone marrow. In CKD, impaired renal function decreases erythropoietin, leading to anemia. This statement is accurate, as it correctly identifies the hormonal deficiency as the primary cause of low RBC counts in CKD.
Full Explanation
Choice A reason: Chronic kidney disease (CKD) does not primarily cause anemia by leaking red blood cells (RBCs) into urine. While hematuria may occur in some renal conditions, anemia in CKD results mainly from reduced erythropoietin production, not RBC loss. This statement is inaccurate, as it misrepresents the primary mechanism of anemia in CKD.
Choice B reason: Inflammation in CKD may contribute to anemia by suppressing erythropoiesis through cytokine release, but it does not directly attack RBCs. The primary cause is erythropoietin deficiency due to impaired renal function. This statement is inaccurate, as it overstates inflammation’s role and ignores the key hormonal mechanism in CKD-related anemia.
Choice C reason: High vascular pressure in CKD can damage kidneys but does not directly cause RBCs to burst (hemolysis). Anemia in CKD stems from reduced erythropoietin, not mechanical RBC destruction. This statement is inaccurate, as it incorrectly links hypertension’s renal effects to direct RBC damage, misrepresenting the anemia’s cause.
Choice D reason: CKD causes anemia due to reduced erythropoietin synthesis by damaged kidneys. Erythropoietin stimulates RBC production in bone marrow. In CKD, impaired renal function decreases erythropoietin, leading to anemia. This statement is accurate, as it correctly identifies the hormonal deficiency as the primary cause of low RBC counts in CKD.
Which patient below is at greatest risk for developing gout?
A. A 45-year-old male with a BMI of 40 taking hydrochlorothiazide and aspirin
Gout results from hyperuricemia, leading to urate crystal deposition in joints. A 45-year-old male with obesity (BMI 40) has increased purine turnover, elevating uric acid. Hydrochlorothiazide reduces urate excretion, and aspirin impairs renal uric acid clearance, significantly increasing gout risk, making this patient the most susceptible due to multiple risk factors.
B. A 39-year-old female hospitalized with bulimia that has a BMI of 24
Bulimia may cause electrolyte imbalances, but it is not strongly linked to hyperuricemia or gout. A BMI of 24 is normal, reducing obesity-related purine production. This 39-year-old female has fewer gout risk factors compared to an obese male on medications that elevate uric acid, making her less likely to develop gout.
C. A 27-year-old female with ulcerative colitis
Ulcerative colitis may cause systemic inflammation, but it is not a direct risk factor for gout. Hyperuricemia is not typically associated with inflammatory bowel diseases unless complicated by other factors like diuretic use. This 27-year-old female has a lower gout risk compared to the obese male with predisposing medications.
D. A 56-year-old male who limits consumption of smoked meat and some cheeses
Limiting purine-rich foods like smoked meat and cheeses reduces uric acid production, lowering gout risk. This 56-year-old male’s dietary habits mitigate hyperuricemia, making him the least likely to develop gout compared to the obese patient on medications that impair uric acid metabolism and excretion.
Full Explanation
Choice A reason: Gout results from hyperuricemia, leading to urate crystal deposition in joints. A 45-year-old male with obesity (BMI 40) has increased purine turnover, elevating uric acid. Hydrochlorothiazide reduces urate excretion, and aspirin impairs renal uric acid clearance, significantly increasing gout risk, making this patient the most susceptible due to multiple risk factors.
Choice B reason: Bulimia may cause electrolyte imbalances, but it is not strongly linked to hyperuricemia or gout. A BMI of 24 is normal, reducing obesity-related purine production. This 39-year-old female has fewer gout risk factors compared to an obese male on medications that elevate uric acid, making her less likely to develop gout.
Choice C reason: Ulcerative colitis may cause systemic inflammation, but it is not a direct risk factor for gout. Hyperuricemia is not typically associated with inflammatory bowel diseases unless complicated by other factors like diuretic use. This 27-year-old female has a lower gout risk compared to the obese male with predisposing medications.
Choice D reason: Limiting purine-rich foods like smoked meat and cheeses reduces uric acid production, lowering gout risk. This 56-year-old male’s dietary habits mitigate hyperuricemia, making him the least likely to develop gout compared to the obese patient on medications that impair uric acid metabolism and excretion.
What is the mechanism of action of sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors)?
A. Blocks glucose reabsorption by the kidneys and increases glucose excretion to lower blood sugar
SGLT-2 inhibitors, like empagliflozin, block sodium-glucose cotransporter 2 in the proximal tubule, preventing glucose reabsorption. This increases urinary glucose excretion, lowering blood sugar in type 2 diabetes. The mechanism is insulin-independent, reducing hyperglycemia and promoting weight loss, making this statement accurate for their primary action.
B. Interacts with the transcription factor that improves insulin sensitivity in the liver, skeletal muscle, and fat
SGLT-2 inhibitors do not interact with transcription factors to improve insulin sensitivity. This describes metformin’s action via AMPK activation in liver and muscle. SGLT-2 inhibitors act renally, not on transcription factors, making this statement inaccurate as it misattributes their mechanism to a different drug class.
C. Inhibits hepatic glucose production and increases insulin sensitivity in peripheral tissues
Inhibiting hepatic glucose production and increasing insulin sensitivity is metformin’s mechanism, not SGLT-2 inhibitors. SGLT-2 inhibitors work renally to excrete glucose, not by altering hepatic gluconeogenesis or peripheral insulin sensitivity. This statement is inaccurate, as it describes a different antidiabetic drug’s action.
D. Blocks ATP-sensitive K+ channels on membrane of beta cells to promote insulin secretion
Blocking ATP-sensitive K+ channels is the mechanism of sulfonylureas, like glipizide, which stimulate insulin secretion from beta cells. SGLT-2 inhibitors act on renal glucose reabsorption, not beta cell channels. This statement is inaccurate, as it incorrectly assigns a sulfonylurea mechanism to SGLT-2 inhibitors.
Full Explanation
Choice A reason: SGLT-2 inhibitors, like empagliflozin, block sodium-glucose cotransporter 2 in the proximal tubule, preventing glucose reabsorption. This increases urinary glucose excretion, lowering blood sugar in type 2 diabetes. The mechanism is insulin-independent, reducing hyperglycemia and promoting weight loss, making this statement accurate for their primary action.
Choice B reason: SGLT-2 inhibitors do not interact with transcription factors to improve insulin sensitivity. This describes metformin’s action via AMPK activation in liver and muscle. SGLT-2 inhibitors act renally, not on transcription factors, making this statement inaccurate as it misattributes their mechanism to a different drug class.
Choice C reason: Inhibiting hepatic glucose production and increasing insulin sensitivity is metformin’s mechanism, not SGLT-2 inhibitors. SGLT-2 inhibitors work renally to excrete glucose, not by altering hepatic gluconeogenesis or peripheral insulin sensitivity. This statement is inaccurate, as it describes a different antidiabetic drug’s action.
Choice D reason: Blocking ATP-sensitive K+ channels is the mechanism of sulfonylureas, like glipizide, which stimulate insulin secretion from beta cells. SGLT-2 inhibitors act on renal glucose reabsorption, not beta cell channels. This statement is inaccurate, as it incorrectly assigns a sulfonylurea mechanism to SGLT-2 inhibitors.